Anticoagulants (VTE & AF) Therapeutics Market

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and
dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.